Skip to main
ARDX

Ardelyx (ARDX) Stock Forecast & Price Target

Ardelyx (ARDX) Analyst Ratings

Based on 9 analyst ratings
Buy
Strong Buy 56%
Buy 33%
Hold 11%
Sell 0%
Strong Sell 0%

Bulls say

Ardelyx Inc's total revenue surpassed consensus estimates by approximately $16 million, driven by a significant $8 million contribution from IBSRELA, leading management to revise its FY25 guidance upward by $10 million. Excluding a one-time benefit, the company demonstrated healthy 27% quarter-over-quarter growth and reiterated its peak U.S. revenue guidance of $750 million before patent expiration. Additionally, XPHOZAH's U.S. net sales exceeded estimates by around $3 million, indicating early success in the company’s strategy amidst changes in Medicare Part D coverage.

Bears say

Ardelyx Inc faces ongoing challenges with its financial outlook due to the loss of Medicare Part D coverage for its product Xphozah, which increases reliance on the non-Medicare patient population that represents only about 40% of the market. The absence of financial guidance for fiscal year 2025 contributes to a heightened sense of uncertainty regarding the company's revenue trajectory and overall financial stability. This strategic pivot, while indicative of adaptability, raises concerns over the sustainability of Ardelyx's current business model amid these constraints.

Ardelyx (ARDX) has been analyzed by 9 analysts, with a consensus rating of Buy. 56% of analysts recommend a Strong Buy, 33% recommend Buy, 11% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Ardelyx and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Ardelyx (ARDX) Forecast

Analysts have given Ardelyx (ARDX) a Buy based on their latest research and market trends.

According to 9 analysts, Ardelyx (ARDX) has a Buy consensus rating as of Dec 25, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $11.22, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $11.22, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Ardelyx (ARDX)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.